StonvexLoading…
StonvexStonvexStonvexCore line items from XBIO's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $2.98M | $2.50M | $2.54M | $1.71M |
Operating Income | $-2.83M | $-4.20M | $-4.52M | $-6.72M |
Net Income | $-2.68M | $-3.96M | $-4.13M | $-6.55M |
EPS (Diluted) | $-1.58 | $-2.57 | $-2.71 | $-4.61 |
Total Assets | $8.36M | $6.90M | $10.61M | $14.72M |
Total Liabilities | $968.02K | $894.26K | $809.59K | $1.07M |
Cash & Equivalents | $7.88M | $6.17M | $8.98M | $13.10M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 2.29M | 1.54M | 1.54M | 1.52M |